Sarepta Therapeutics Inc Q3 2021 Earnings Call Summary

The following is excerpted from the question-and-answer section of the transcript.

Question: Gil Joseph Blum - Needham & Company, LLC, Research Division - Analyst : Congratulations on a very strong quarter. But maybe a bit of a question on PPMOs more broadly. So we can reach around 80% of patients. But so far, in the PMO programs, you had to kind of approve each new targeted population by itself. Is there a basket approach here somewhere, maybe kind of like what you're looking at LGMD?

Question: Colin Nigel Bristow - UBS Investment Bank, Research Division - Analyst : Just a Part 2 of Study 102 and the potential for this to permit a discussion with the FDA around an expedited path to market. What is the minimum you guys are looking for to initiate that conversation with the agency?

Question: Yun Zhong - BTIG, LLC, Research Division - Analyst : So PPMO program, can you remind us if 5051 is using the same sequence as EXONDYS 51? And how quickly do you think you will be able to move additional programs whether you take basket approach or not into the clinic? And also, you talked about ex U.S. opportunity. But given what you previously experienced with EXONDYS 51 when you talked to the EMA, are you going to look at functional endpoint at all with either 5051 study or maybe future studies?